All In Biotech

Drug Trial Radar · NCT04348136

An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

27

Actual

Start

Sep 1, 2019

Primary completion

Mar 31, 2030

Study completion Mar 31, 2030

Sponsor

Lead sponsor
JCR Pharmaceuticals Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the MPS II.

Conditions

  • Mucopolysaccharidosis II

Interventions

  • JR-141Drug

    IV infusion, 2.0 mg/kg/week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of adverse eventsTime frame: From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years
  2. Occurrence of adverse reactionsTime frame: From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years
  3. Incidence of abnormal vital signsTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  4. Incidence of abnormal vital signsTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  5. Incidence of abnormal vital signsTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  6. Laboratory tests (urinalysis)Time frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  7. Vital signs (pulse rate)Time frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  8. Vital signs (body temperature)Time frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  9. Vital signs (blood pressure)Time frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  10. 12-lead electrocardiogramTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  11. Antibody tests (anti-JR-141 antibodies)Time frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  12. IARTime frame: From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years
  13. Time course of developmental assessment data (Kyoto Scale of Psychological Development 2001) from initial dosing in the preceding studyTime frame: Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  14. Time course of developmental assessment data (Vineland-II) from initial dosing in the preceding studyTime frame: Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  15. Time course of developmental assessment data (Bayley-III or KABC-II) from initial dosing in the preceding studyTime frame: Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  16. Time course of CSF substrate (HS and DS) concentrations from initial dosing in the preceding studyTime frame: Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  17. Time course of serum HS and DS concentrations from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  18. Time course of urinary HS concentration from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  19. Time course of urinary DS concentration from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  20. Time course of uronic acid concentration from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  21. Time course of liver volume (assessed by CT or MRI) from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  22. Time course of spleen volume (assessed by CT or MRI) from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  23. Time course of cardiac function (assessed by echocardiography) from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  24. Time course of 6-minute walk test distance from initial dosing in the preceding studyTime frame: Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  25. Time course of joint range of motion from initial dosing in the preceding studyTime frame: Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Fukui Clinical site

    Fukui, Japan

  • Fukuoka Clinical site 2

    Fukuoka, Japan

  • Fukuoka Clinical site

    Fukuoka, Japan

  • Gifu Clinical site

    Gifu, Japan

  • Hiroshima Prefectural Hospital

    Hiroshima, Japan

  • Hokkaido Clinical site

    Hokkaido, Japan

  • Kananagawa Ckinical site

    Kanagawa, Japan

  • Kumamoto Clinical site

    Kumamoto, Japan

  • Okayama Clinical site

    Okayama, Japan

  • Okayama Clinical site 2

    Okayama, Japan

  • Okinawa Clinical site

    Okinawa, Japan

  • Osaka Clinical site 3

    Osaka, Japan

  • Osaka Clinical site 2

    Osaka, Japan

  • Osaka Clinical site

    Osaka, Japan

  • Saitama Clinical site

    Saitama, Japan

  • Shizuoka Clinical site

    Shizuoka, Japan

  • Shizuoka Clinical site 2

    Shizuoka, Japan

  • Tochigi Clinical site

    Tochigi, Japan

  • Tokyo Clinical site

    Tokyo, Japan

  • Tottori Clinical site

    Tottori, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.